USA flag logo/image

An Official Website of the United States Government

TARGETING OF PLASMINOGEN ACTIVATORS IN MYOCARDIAL INFARCT

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
8069
Program Year/Program:
1988 / SBIR
Agency Tracking Number:
8069
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Proteins International Inc
1858 Star Batt Dr Rochester Hills, MI 48309
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1988
Title: TARGETING OF PLASMINOGEN ACTIVATORS IN MYOCARDIAL INFARCT
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE LONG-TERM OBJECTIVE OF THIS PROJECT IS THE DEVELOPMENT AND CHARACTERIZATION OF CONJUGATES BETWEEN PLASMINOGEN ACTIVATORS (UROKINASE, TISSUE PLASMINOGEN ACTIVATOR, SINGLE CHAIN UROKINASE) AND MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN CARDIAC HEAVY CHAIN MYOSIN. THIS TYPE OF CONJUGATE BYSELECTIVELY TARGETING THE PLASMINOGEN ACTIVATOR TO DAMAGED MYOCYTES IN THE AREA OF THE THROMBUS, SHOULD SIGNIFICANTLY REDUCE SYSTEMIC PLASMINOGEN ACTIVATION AND THE ASSOCIATED DELETERIOUS EFFECTS. THE INITIAL PHASE OF THIS RESEARCH WILL BE DIRECTED TOWARD COVALENTLY COUPLING UROKINASE WITH ANTI-MYOSIN ANTIBODIES AND CHARACTERIZING THE RESULTING CONJUGATES FOR PLASMINOGEN ACTIVATING ACTIVITY AND MYOSIN BINDING AVIDITY. IN VITRO TESTING OF THE CONJUGATES WILL BE DONE TO DETERMINE THE DISTANCE FROM THE MYOSIN BINDING SITES WHEREIN PLASMIN PRODUCED BY THE CONJUGATE CAN EFFECT FIBRINOLYSIS. IN ADDITION TO POTENTIAL DEVELOPMENT OF AN IMPROVED THROMBOLYTIC AGENT FOR CLINICAL USE, THESE STUDIES MAY LEAD TO THE DEVELOPMENT OF A MORE GENERAL APPROACH FOR TARGETING SPECIFIC ENZYMES TO PATHOLOGICAL SITES.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Proteins International
1858 Star Batt Dr Rochester, MI 48063

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No